Apparatus for purifying extracorporeal blood by removing active oxygen and method for purifying extracorporeal blood using same
The preparation of an in vitro blood purification device through porous microbeads loaded with ceria nanoparticles has solved the problem of ineffective removal of reactive oxygen species in the prior art, achieved continuous removal of reactive oxygen species, improved the symptoms of systemic inflammatory response syndrome such as sepsis, improved survival rate and reduced lactate levels.
Patent Information
- Application Number
- CN202480008257.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-19
- Filing Date
- 2024-01-19
- Publication Date
- 2025-08-26
AI Technical Summary
Existing in vitro blood purification therapy cannot effectively remove reactive oxygen, resulting in tissue damage and organ dysfunction, and existing blood purification devices cannot continuously remove reactive oxygen.
Porous microbeads supported by ceria nanoparticles were used to remove reactive oxygen by catalytic action, and an in vitro blood perfusion box and purification device were prepared, and the porous microbeads were used to contact the blood and remove reactive oxygen.
Effectively remove reactive oxygen species in the blood, improve the severity of severe diseases related to systemic inflammatory response syndrome, improve survival rate and reduce lactate levels, and ensure safety.
Smart Images

Figure CN120548202A_ABST
Abstract
Description
Technical Field
[0001] This specification discloses an extracorporeal blood purification device and an extracorporeal blood purification method using the device.
[0002] At the same time, this application is supported by the following R&D projects.
[0003] [R&D projects supporting this invention]
[0004] [Project ID] 2022R1C1C100961012
[0005] [Department Name] Ministry of Science, Technology, Information and Communications
[0006] [Administering Agency] National Research Foundation of Korea
[0007] [Project Name] Basic Research Projects in Science and Engineering > New Research Support Projects > Excellent New Research
[0008] [Project Name] Development of an extracorporeal blood purification system based on multifunctional microbeads for the treatment of sepsis
[0009] [Contribution rate] 60 / 100
[0010] [Supervisory agency] Seoul National University Bundang Hospital
[0011] [Study Period] March 1, 2022 - February 28, 2025
[0012] [Project Number] RS-2023-00222910
[0013] [Department Name] Ministry of Science, Technology, Information and Communications
[0014] [Administering Agency] National Research Foundation of Korea
[0015] [Project Name] Biological and medical technology development (R&D)
[0016] [Project Name] Development of applied technologies in the five major disease medical fields and training of medical scientists through a customized future medical research center in the 6P medical era
[0017] [Contribution rate] 35 / 100
[0018] [Supervisory agency] Seoul National University Bundang Hospital
[0019] [Study Period] April 1, 2023 - December 31, 2026
[0020] [Project Number] 13-2021-0004
[0021] [Department Name] Seoul National University Bundang Hospital
[0022] [Management Professional Institution] Seoul National University Bundang Hospital
[0023] [Project Name] Joint Research in Key Support Areas
[0024] [Project Name] Development of extracorporeal blood purification equipment based on nanomaterials for the treatment of cytokine storm
[0025] [Contribution rate] 5 / 100
[0026] [Supervisory agency] Seoul National University Bundang Hospital
[0027] [Study Period] March 1, 2021 - March 1, 2024 Background Art
[0028] Sepsis is essentially a severe infection accompanied by a systemic inflammatory response. Sepsis can develop into a life-threatening condition due to the body's excessive and inappropriate response to infection, leading to tissue damage and organ dysfunction. Systemic inflammatory response syndrome (SIRS), a systemic inflammatory response manifested by the body in response to various forms of severe stress or injury, such as infection, trauma, burns, and pancreatitis, also plays a significant pathophysiological role in sepsis. To date, a variety of drugs have been developed and clinically tested for the treatment of sepsis, but their effectiveness has not yet been proven. As a new approach to treating sepsis, blood purification therapies (such as Toraymyxin and Cytosorb) have been developed and highly anticipated. These therapies can remove pathogen-related substances or cytokines in vitro, but have not been successful in clinical trials and are not recommended by clinical diagnosis and treatment guidelines. Reactive oxygen species are a major factor in triggering tissue damage and organ dysfunction. In SIRS, such as sepsis, excessive production or inadequate removal of reactive oxygen species causes cell damage and promotes inflammation. However, existing blood purification therapies have the significant limitation of being unable to effectively remove reactive oxygen species. Summary of the Invention Technical issues
[0029] An object of the present invention is to provide porous microbeads for extracorporeal blood perfusion, an extracorporeal blood perfusion box containing the porous microbeads, or an extracorporeal blood purification device including the extracorporeal blood perfusion box.
[0030] Another object of the present invention is to provide a method for preparing the porous microbeads.
[0031] Another object of the present invention is to provide an extracorporeal blood purification method using the porous microbeads. Technical Solution
[0032] To achieve the above objectives, in one aspect, the present invention provides porous microbeads for in vitro blood perfusion, comprising cerium dioxide nanoparticles.
[0033] In an exemplary embodiment, the porous microbeads can remove active oxygen through the catalytic effect of cerium dioxide nanoparticles.
[0034] In yet another aspect, the present invention provides an extracorporeal blood perfusion box comprising the porous microbeads.
[0035] In another aspect, the present invention provides an extracorporeal blood purification device comprising the extracorporeal blood perfusion box.
[0036] In yet another aspect, the present invention provides an extracorporeal blood purification method comprising:
[0037] Step (a), contacting blood separated from a subject with the porous microbeads;
[0038] Step (b), removing active oxygen from the blood using the porous microbeads; and
[0039] Step (c), recovering the blood from which the active oxygen has been removed.
[0040] In another aspect, the present invention provides a method for preparing the porous microbeads for in vitro blood perfusion, comprising:
[0041] Step (a), synthesizing porous microbeads and modifying their surfaces; and
[0042] Step (b) attaching cerium dioxide nanoparticles to the surface of the modified porous microbeads. Effects of the Invention
[0043] In one aspect, the present invention can effectively remove reactive oxygen species (ROS) in the blood in vitro by loading porous microbeads of cerium dioxide nanoparticles, and reactive oxygen species are substances that cause inflammation. Specifically, in order to be able to load the porous microbeads on a blood perfusion box to perfuse the patient's blood, an extracorporeal blood purification device is prepared, which can widely and quickly remove reactive oxygen species under aqueous solution and blood conditions. Therefore, the present invention can be applied to an extracorporeal blood perfusion treatment system based on microbeads.
[0044] In another aspect, the present invention can continuously remove reactive oxygen species. In particular, to address the difficulty in continuously removing reactive oxygen species in an in vitro perfusion environment, the present invention can achieve continuous removal of reactive oxygen species by using a catalyst (cerium dioxide nanoparticles) rather than an adsorbent.
[0045] On the other hand, inorganic nanoparticles such as cerium dioxide nanoparticles are difficult to develop as drugs because they are difficult to ensure safety when injected into the body. However, the present invention has the advantage of ensuring safety by removing active oxygen by perfusing blood outside the body.
[0046] On another aspect, unlike existing extracorporeal perfusion treatments that non-specifically adsorb all substances that may be helpful to patients (such as cytokines), the present invention selectively removes reactive oxygen species, which is the root cause of inflammatory damage reactions, thereby solving the problems existing in existing extracorporeal blood perfusion devices.
[0047] On the other hand, the present invention can remove elevated reactive oxygen species in severe diseases related to systemic inflammatory response syndrome such as sepsis through extracorporeal perfusion, improve severity indicators (such as blood pressure, pressor dosage, lactate level), and improve survival rate.
[0048] In yet another aspect, the present invention can be applied to a microbead-based extracorporeal hemoperfusion therapy system that can remove substances that cause inflammation, namely reactive oxygen species (ROS). BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 Schematic diagram of a microbead-based hemoperfusion system for removing reactive oxygen species in a sepsis model.
[0050] Figure 2 The preparation process of porous silica microbeads is shown.
[0051] Figure 3 Representative images of various steps in the preparation of porous silica microbeads from porous silica particles / alginate microbeads.
[0052] Figure 4 Shown are nitrogen (N2) physisorption isotherms and pore size of porous silica microbeads as the final product according to the porous silica particle content (wt%) during the preparation process of the initial porous silica particles / alginate microbeads (square: 1 wt%, triangle: 3 wt%, diamond: 5 wt%).
[0053] Figure 5 The process of preparing ceria nanoparticles / porous silica microbeads by attaching ceria nanoparticles to the surface of porous silica microbeads by electrostatic attraction is shown.
[0054] Figure 6 The surface charge (zeta-potential) of porous silica particles and ceria nanoparticles is shown.
[0055] Figure 7Representative photos of porous silica microbeads and ceria nanoparticles / porous silica microbeads with attached ceria nanoparticles.
[0056] Figure 8 Shown are SEM images of porous silica microbeads and ceria nanoparticles / porous silica microbeads, and analysis of the distribution of cerium (Ce) atoms in the microbead surfaces using EDS.
[0057] Figure 9 Schematic diagram of cerium dioxide nanoparticles / porous silica microbeads coated with polyvinyl pyrrolidone (PVP).
[0058] Figure 10 The results of thermogravimetric analysis (TGA) of porous silica microbeads, ceria nanoparticles / porous silica microbeads, and PVP-coated ceria nanoparticles / porous silica microbeads are shown.
[0059] Figure 11 Shown are catalase-mimicking activities measured by a hydrogen peroxide / peroxidase assay with incubation time in H2O2 (500 μM) using porous silica microbeads, ceria nanoparticles / porous silica microbeads, and PVP-coated ceria nanoparticles / porous silica microbeads.
[0060] Figure 12 The figure shows the hydroxyl radical scavenging activities of porous silica microbeads, ceria nanoparticles / porous silica microbeads, and PVP-coated ceria nanoparticles / porous silica microbeads measured using the HORAC assay kit.
[0061] Figure 13 The catalase-mimicking activity generated according to the amount of cerium oxide nanoparticles contained in the microbeads is shown.
[0062] Figure 14 Representative images of cartridges fabricated to carry microbeads.
[0063] Figure 15 Representative images of the cassettes loaded with porous silica microbeads, ceria nanoparticles / porous silica microbeads, and PVP-coated ceria nanoparticles / porous silica microbeads, respectively.
[0064] Figure 16The graph shows the catalase-simulated activity when hydrogen peroxide was flowed through cartridges containing 220 g of porous silica microbeads, ceria nanoparticles / porous silica microbeads, and PVP-coated ceria nanoparticles / porous silica microbeads, respectively, and the hydrogen peroxide flowing through the cartridges was recovered and the flow was repeated up to 7 times.
[0065] Figure 17 Shown is the catalase mimetic activity measured each time a fresh hydrogen peroxide solution was passed through the cartridge containing PVP-coated ceria nanoparticles / porous silica microbeads and the solution was recovered.
[0066] Figure 18 The present invention shows a cartridge made by loading ceria nanoparticles onto non-porous glass microbeads and porous polyethersulfone (PES) polymer microbeads, as well as a cartridge containing PVP-coated ceria nanoparticles / porous silica microbeads, and compares their catalase mimetic properties.
[0067] Figure 19 Representative images of microbeads after mixing with blood and centrifugation to demonstrate the hemocompatibility of the microbeads.
[0068] Figure 20 The degree of hemolysis based on absorbance analysis of the supernatant is shown.
[0069] Figure 21 Representative images of centrifuged microbeads after washing and removing blood from the centrifuged microbeads.
[0070] Figure 22 During the actual extracorporeal hemoperfusion treatment process, images of blood flowing out of the body and into the box are taken in chronological order.
[0071] Figure 23 The graph compares the difference in hydrogen peroxide (H2O2) levels released from leukocytes extracted from the blood of rats subjected to the hemoperfusion treatment group and a control group in which sepsis was induced.
[0072] Figure 24 This graph compares the difference in blood lactate (a marker of septic shock) levels between the group in which sepsis-induced rats were treated with the hemoperfusion therapy and the control group.
[0073] Figure 25 The graph compares the difference in survival rate between the group receiving the hemoperfusion treatment and the control group in rats with induced sepsis.
[0074] Figure 26 This figure compares the difference in blood pressure between the group receiving the hemoperfusion treatment and the control group in rats with induced sepsis.
[0075] Figure 27 The figure compares the difference in pressor dosage reflecting the degree of shock between the group receiving the hemoperfusion treatment and the control group in rats with induced sepsis. DETAILED DESCRIPTION
[0076] The present invention will be described in detail below.
[0077] In one aspect, the present invention relates to porous microbeads for in vitro blood perfusion, comprising ceria nanoparticles.
[0078] In an exemplary embodiment, the porous microbeads can remove active oxygen through the catalytic effect of cerium dioxide nanoparticles.
[0079] In an exemplary embodiment, the size (diameter) of the porous microbeads can be 1 μm or more, 10 μm or more, 100 μm or more, 150 μm or more, 200 μm or more, 250 μm or more, 300 μm or more, 350 μm or more, 400 μm or more, 450 μm or more, or 1500 μm or less, 1400 μm or less, 1300 μm or less, 1200 μm or less, 1100 μm or less, 1000 μm or less, 900 μm or less, 800 μm or less, 700 μm or less, 650 μm or less, 600 μm or less, 550 μm or less, but are not limited thereto. For example, the size (diameter) of the porous microbeads can be 1 to 1500 μm, or 10 to 1000 μm, or 100 to 1000 μm. The size (diameter) of the porous microbeads can be adjusted considering the size of the cartridge and effective blood perfusion. Meanwhile, in a non-limiting example, the size (diameter) of the porous microbeads may be larger than that of blood cells, for example, larger than 10 μm.
[0080] In an exemplary embodiment, the active oxygen species may be at least one selected from the group consisting of superoxide anion, hydrogen peroxide, hydroxyl radical, and combinations thereof, but is not limited thereto.
[0081] In an exemplary embodiment, the porous microbeads may have a pore volume of 0.1 cm 3 / g to 13.5cm 3 / g, preferably, it can be 0.1cm 3 / g to 5.0cm 3 / g, more preferably, it can be 0.5cm 3 / g to 1.5cm 3The porous microbeads having the pore volume can effectively load cerium dioxide nanoparticles and remove active oxygen.
[0082] In an exemplary embodiment, the surface area of the porous microbeads may be 100 m 2 / g to 1000m 2 / g, preferably, 150m 2 / g to 600m 2 / g, more preferably, 200m 2 / g to 400m 2 The porous microbeads having such a surface area can effectively load cerium dioxide nanoparticles and remove active oxygen.
[0083] In an illustrative embodiment, the porous microbeads may contain 3 mg / g or more of ceria nanoparticles, specifically, 3 mg / g or more, 4 mg / g or more, 5 mg / g or more, 10 mg / g or more, 15 mg / g or more, 20 mg / g or more, 30 mg / g or more, 40 mg / g or more, or 50 mg / g or less, 400 mg / g or less, or 300 mg / g or less, but not limited thereto. For example, porous microbeads in a box containing 100 mg / g or 200 mg / g of ceria nanoparticles can effectively perform in vitro blood perfusion and reactive oxygen species removal.
[0084] In an exemplary embodiment, the porous microbeads can be one or more selected from the group consisting of porous microbeads coated with alginate, porous microbeads coated with polyethylene glycol (PEG), porous microbeads coated with polyvinyl pyrrolidone (PVP), and combinations thereof. By coating, the reactivity between the porous microbeads and the blood can be prevented, thereby inhibiting hemolysis or aggregation and improving the blood compatibility of the porous microbeads. From this aspect, preferably, the porous microbeads are coated with PEG (polyethylene glycol) or PVP (polyvinylpyrrolidone), and more preferably, the porous microbeads are coated with PVP (polyvinylpyrrolidone).
[0085] In an exemplary embodiment, the porous microbeads may be selected from the group consisting of mesoporous silica, styrene, C1-C4 alkyl-substituted styrene, vinylnaphthalene, vinylanthracene, cellulose, styrene-divinyl-benzene copolymer, polyethersulfone (PES), polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), polyurethane (PUR), polyethylene terephthalate (PET), polystyrene (PS), acrylonitrile butadiene styrene (ABS), polymethyl methacrylate (PMMA), polytetrafluoroethylene (PTFE), expanded polystyrene (EPS ...vinyl chloride (PVC), polyurethane (PUR), polyvinyl chloride (PES), polyvinyl chloride (PVC), polyurethane (PUR), polyvinyl chloride (PES), polyvinyl chloride (PVC), polyurethane (PUR), polyvinyl chloride (PET), polyvinyl chloride (PS), polyvinyl chloride (ABS), polyvinyl chloride (PVC), polyvinyl chloride (PVC), polyurethane (PUR), polyvinyl chloride (PES), polyvinyl chloride (PES), polyvinyl chloride (PVC), polyurethane (PUR), polyvinyl chloride (PET), polystyrene (PS), acrylonitrile butadiene styrene (ABS), polymethyl methacrylate (PMMA), polytetrafluoroethylene (PTFE), expanded polystyrene (EPS), polyvinyl chloride (PES), polyvinyl chloride (PVC), polyvinyl chloride (PVC), polyurethane (PUR), polyvinyl chloride (PES), polyvinyl chloride (PES), polyvinyl chloride (PVC), polyurethane (PUR), polyvinyl chloride (PES), polyvinyl chloride ( The porous microbeads may be selected from the group consisting of, but not limited to, polystyrene (EPS), polycarbonate (PC), polyamide (PA), epoxy resin, unsaturated polyester (UP), melamine-formaldehyde resin (MF) and combinations thereof. Suitable C1-C4 alkyl-substituted styrenes may include, but not limited to, ethylvinylbenzene, vinyltoluene, diethylstyrene, ethylmethylstyrene or dimethylstyrene. It is understood that various positional isomers of each of the above-mentioned vinyl aromatic monomers are suitable. For example, the porous microbeads may be mesoporous silica microbeads, but any porous microbeads having the above-mentioned properties such as pore volume, surface area, and ceria nanoparticle loading capacity may be used without limitation.
[0086] In yet another aspect, the present invention relates to an extracorporeal blood perfusion box comprising the porous microbeads.
[0087] In one exemplary embodiment, the volume ratio of the porous microbeads to the total volume of the extracorporeal hemoperfusion cassette can be greater than 50%, greater than 55%, greater than 60%, greater than 65%, or greater than 70%, or less than 90%, less than 85%, or less than 80%. For example, the volume ratio of the porous microbeads to the total volume of the extracorporeal hemoperfusion cassette can be between 50% and 90%, but is not limited thereto. At these volume ratios, effective extracorporeal hemoperfusion and reactive oxygen species removal can be achieved.
[0088] In another aspect, the present invention relates to an extracorporeal blood purification device comprising the extracorporeal blood perfusion box.
[0089] In yet another aspect, the present invention relates to a method for extracorporeal blood purification, comprising:
[0090] Step (a), contacting blood separated from a subject with the porous microbeads;
[0091] Step (b), removing active oxygen from the blood using the porous microbeads; and
[0092] Step (c), recovering the blood from which the active oxygen has been removed.
[0093] In one exemplary embodiment, the step of removing reactive oxygen species may be performed for 2 to 24 hours, but the present invention is not limited thereto. The porous microbeads can continuously remove reactive oxygen species by using a catalyst (cerium dioxide nanoparticles) rather than an adsorbent. Therefore, the reactive oxygen species can be continuously removed for a desired period of time, without being limited by time.
[0094] In another aspect, the present invention provides a method for preparing the porous microbeads for in vitro blood perfusion, comprising: step (a), synthesizing the porous microbeads and modifying their surfaces; and step (b), attaching cerium dioxide nanoparticles to the surface of the modified porous microbeads.
[0095] In an exemplary embodiment, in step (a), the surface of the porous microbeads may be modified using an agent comprising one or more functional groups selected from the group consisting of amine, thiol, and carboxylic groups.
[0096] In an exemplary embodiment, the method may further include: step (c), coating a polymer on the surface of the porous microbeads to which the cerium oxide nanoparticles are attached.
[0097] In an exemplary embodiment, in step (c), at least one selected from the group consisting of porous microbeads coated with alginate, porous microbeads coated with PEG (polyethylene glycol), porous microbeads coated with polyvinylpyrrolidone (PVP), and combinations thereof may be prepared, but the invention is not limited thereto. Modes for Carrying Out the Invention
[0098] The present invention will be described in more detail below by way of examples. These examples are only used to illustrate the present invention, and it is obvious to those skilled in the art that the scope of the present invention should not be construed as being limited by these examples.
[0099] [Example 1]
[0100] Experimental Materials and Methods
[0101] (1-1) Experimental Materials
[0102] Mesitylene, Ammonium fluoride, Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol))( P-123 (Mn-5800), hydrochloric acid, nitric acid, alginic acid sodium salt from brown algae, sodium bicarbonate, tetraethyl orthosilicate, 6-aminohexanoic acid, ethanol, isopropanol, and acetone were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cerium (III) nitrate hexahydrate was purchased from Alfa Aesar. Methoxy PEG-amidesuccinimidyl glutarate 5000 was purchased from SunBio (Anyang, South Korea). All reagents were used directly without further purification.
[0103] (1-2) Synthesis of Millimeter-Scale Porous Silica Microbeads
[0104] Using an organic template, porous silica microbeads were synthesized by the silica sol-gel method. Specifically, (1) 16 g of P-123, 80 mL of HCl, 4 mL of 46 mg / mL ammonium fluoride, and 12 g of TMB were dissolved in 516 mL of deionized water (DI water) and stirred at 50°C for 4 hours. Then, 36.8 mL of TEOS was added to the mixture and reacted for 20 hours. After that, the synthesized porous silica particles were subjected to a hydrothermal reaction at 100°C for 24 hours, and the generated porous silica particles were filtered and dried. (2) 10 mL of 20 mg / mL alginate solution and 10 mL of 20, 60, and 100 mg / mL porous silica particles were mixed and injected into a 100 mM CaCl2 solution using a 12 kV high-voltage electrospray method using a syringe pump to synthesize porous silica / alginate microbeads. The silica precursor, obtained by reacting 17 mL of 0.15 M HNO₃ with 68 mL of TEOS for one hour, was then mixed with the porous silica / alginate microbeads and allowed to react for 24 hours. After the reaction, the recovered microspheres were washed with IPA and dried, then sintered at 550°C for six hours to remove the alginate and P123, thereby creating pores and ultimately yielding porous silica microbeads.
[0105] (1-3) Synthesis of Ceria Nanoparticles
[0106] 1.3117 g of 6-aminohexanoic acid and 70 μL of HCl were dissolved in 60 mL of deionized water (DI water) and heated to 95°C. Next, 1.08557 g of cerium (III) nitrate hexahydrate was added to the mixture and allowed to react for 1 minute. The synthesized cerium dioxide nanoparticles were precipitated in 500 mL of acetone, then centrifuged three times at 10,000 rpm for 10 minutes each, washed, and dried in a vacuum oven for 24 hours. The dried cerium dioxide nanoparticles were redispersed in deionized water (DI water) and stored at 4°C for later use.
[0107] (1-4) Preparation of Cerium Oxide Nanoparticles / Porous Silica Microbeads
[0108] Since the surface of porous silica microbeads carries a (-) charge, while ceria nanoparticles carry a (+) charge, the polarity difference can be used to induce electrostatic bonding to prepare ceria nanoparticles / porous silica microbeads. 1 g of porous silica microbeads was mixed with 20 mL of a 5 mg / mL ceria nanoparticle solution and reacted for 24 hours. Then, the mixture was washed three times with deionized water and acetone, respectively, and dried in a vacuum oven for 24 hours. The amount of ceria nanoparticles present in the supernatant was measured by ICP-MS, and the loading efficiency of the ceria nanoparticles was calculated by the difference between the amount of the mixed ceria nanoparticles and the amount of the mixed ceria nanoparticles.
[0109] (1-5) Preparation of PEG-coated Cerium Dioxide Nanoparticles / Porous Silica Microbeads
[0110] To coat the porous silica microbeads with polyethylene glycol (PEG), 500 mg of methoxy PEG-amide succinimidyl glutarate 5000 was dissolved in sodium bicarbonate buffer (pH 8.0). 1 g of ceria nanoparticles / porous silica microbeads was added to the mixture and mixed for 24 hours. After the reaction, the PEG-coated ceria nanoparticles / porous silica microbeads were washed three times with deionized water and stored at 4°C until use.
[0111] (1-6) Preparation of PVP-coated Cerium Dioxide Nanoparticles / Porous Silica Microbeads
[0112] Dissolve 1g of polyvinylpyrrolidone (PVP) in deionized water and mix with 1g of ceria nanoparticles / porous silica microbeads. Allow to react for 24 hours. After the reaction, wash the PVP-coated ceria nanoparticles / porous silica microbeads three times with deionized water and store in deionized water at 4°C until ready for use.
[0113] (1-7) Characteristic Analysis of Porous Silica Microbeads
[0114] The surface morphology and elements of all microbeads were analyzed by SEM and EDS (JSM 7000F, JEOL, Japan). The pore size, pore volume, and surface area were measured using the Brunauer-Emmett-Teller (BET) surface area method.
[0115] (1-8) Analysis of the ROS removal ability of microbeads in vitro
[0116] 10, 25, 50 mg of porous silica microbeads, ceria nanoparticles / porous silica microbeads and 500 μM hydrogen peroxide (H2O2) solution were mixed. After 2 hours of reaction, 50 μL of supernatant was recovered and mixed with 50 μL of working solution containing 100 μM AmplexRed reagent and 0.2 U / mL horseradish peroxidase (HRP), and the reaction was carried out at room temperature for 30 minutes. The reaction product resorufin was detected using a microplate reader (Varioskan LUX, Thermo Fisher Scientific, Massachusetts, USA), and fluorescence was detected with an excitation wavelength of 545 nm and an emission wavelength of 590 nm. The hydroxyl radical antioxidant capacity of porous silica microbeads and ceria nanoparticles / porous silica microbeads was measured using the HORAC Activity Assay Kit. 10 mg of porous silica microbeads and ceria nanoparticles / porous silica microbeads were prepared in a 1.5 mL tube. 40 μL of deionized water, 280 μL of fluorescein probe, 40 μL of hydroxyl radial initiator, and 40 μL of Fenton reagent were added to the porous silica microbeads and ceria nanoparticles / porous silica microbeads, and the tubes were incubated with gentle shaking at room temperature for 60 minutes. 200 μL of the sample solution was recovered and measured every 5 minutes at an excitation wavelength of 480 nm and an emission wavelength of 530 nm for a total of 1 hour (Varioskan LUX, Thermo Fisher Scientific, Massachusetts, USA). All measurements were performed at least three times.
[0117] (1-9) In vitro ROS removal analysis using microbeads from the kit system
[0118] A box with a volume of about 1 mL was made and equipped with 8 mm mesh filters at the top and bottom of the box to prevent particles from escaping. 200 mg of porous silica microbeads, ceria nanoparticles / porous silica, and PVP-coated ceria nanoparticles / porous silica microbeads were prepared in the box. A 2 mM hydrogen peroxide (H2O2) solution was added to the top at a flow rate of 1 mL / min using a syringe pump for 10 minutes. After 10 minutes, 50 μL of the sample was transferred to a 96-well plate and the remaining H2O2 solution was re-injected into the box for 1, 2, 4, and 7 cycles. The hydrogen peroxide removal efficiency was calculated using the same method (Amplex Assay Kit).
[0119] (1-10) Microbeads adsorption test on blood
[0120] The blood adsorption test was performed as follows: 10 mg of porous silica microbeads, ceria nanoparticles / porous silica microbeads, or PVP-coated ceria nanoparticles / porous silica microbeads were added to 10 mL of blood and incubated at 37° C. for 2 hours.
[0121] (1-11) Analysis of therapeutic effects using microbeads in a box system
[0122] A 5 mg / kg dose of endotoxin (lipopolysaccharide (LPS)) was intravenously infused into rats (Rat) to induce sepsis. Catheters were inserted into the carotid artery, femoral artery, and femoral vein, and connected to the blood perfusion circuit, box, and perfusion pump. The control group was not connected to the box. Ten minutes after the induction of sepsis, the perfusion pump was operated at a rate of 1.5 ml / min to perform extracorporeal blood circulation. After the induction of sepsis, 30 ml / kg of normal saline was infused intravenously, and when the mean arterial pressure dropped below 60 mmHg, norepinephrine (norepinephrine) was infused as a pressor at a maximum rate of 1 mcg / kg / min. Extracorporeal blood circulation was terminated after 4 hours. The death of the rats, mean arterial pressure, and the amount of pressor used were observed and recorded within 4 hours. In the experiments to measure blood lactate levels and the level of hydrogen peroxide released by leukocytes, blood was collected at 1 hour for comparison to eliminate the bias caused by individual deaths.
[0123] [Example 2]
[0124] Characteristic analysis results of porous silica microbeads
[0125] Porous silica microbeads ( Figure 3). Then, the porous silica microparticles are induced to bond together in the porous silica / alginate hydrogel through the silica sol-gel reaction, and then the alginate and P123 as organic matter are removed through calcination, and finally porous silica microbeads are obtained. It has been observed that the alginate hydrogel microbeads without porous silica particles are greatly reduced in size and distorted in shape after the same process. The alginate hydrogel microbeads containing porous silica microparticles maintain a similar size after calcination. In order to control the porosity of the porous silica microbeads, porous silica microbeads are prepared by changing the concentration of porous silica microparticles contained in the alginate hydrogel ( Figure 4 ). According to the concentration of porous silica particles, the surface area and pore volume are: at 1wt%, the surface area is 207.33m 2 / g, pore volume 0.45cm 3 / g; at 3wt%, the surface area is 244.73m 2 / g, pore volume 0.56cm 3 / g; at 5wt%, the surface area is 395.17m 2 / g, pore volume 0.84cm 3 / g. This indicates that porosity (surface area and pore volume) increases with increasing porous silica particle concentration. Although a high porosity was preferred in the experiments, the high viscosity of an alginate solution containing 5 wt% porous silica resulted in low productivity. Therefore, a 3 wt% porous silica concentration was used in subsequent experiments.
[0126] [Example 3]
[0127] Loading efficiency of ceria nanoparticles / porous silica microbeads for ceria nanoparticles
[0128] Cerium dioxide nanoparticles have a positive surface charge and can be easily adsorbed on the surface of negatively charged porous silica microbeads ( Figure 5 and Figure 6 ). 1g of porous silica microbeads and 20mL of 5mg / mL ceria nanoparticles were mixed to allow the ceria nanoparticles to adsorb onto the porous silica microbeads. The result was ceria nanoparticles / porous silica microbeads, whose color changed slightly to yellow due to the loaded ceria nanoparticles ( Figure 7). In addition, the supernatant (remaining cerium dioxide nanoparticles) after mixing the cerium dioxide nanoparticles and the porous silica microbeads was subjected to ICP-MS analysis, and the results showed that the loading efficiency was 100%. Through SEM observation, the surface of the porous silica microbeads showed a combination of uneven and smooth clusters, while the surface of the cerium dioxide nanoparticles / porous silica microbeads showed a rough texture throughout the clusters. Energy-dispersive X-ray Spectroscopy (EDS) confirmed that a certain amount of Ce element was detected in the cerium dioxide nanoparticles / porous silica microbeads, indicating that the cerium dioxide nanoparticles were adsorbed ( Figure 8 ).
[0129] [Example 4]
[0130] Blood compatibility analysis of PVP-coated ceria nanoparticles / porous silica microbeads
[0131] To analyze blood compatibility, PVP was coated on ceria nanoparticles / porous silica microbeads by physical adsorption ( Figure 9 ). 1 g of cerium dioxide nanoparticles / porous silica microbeads was mixed with 20 mL of 50 mg / mL PVP aqueous solution and reacted for 24 hours. The mixture was then washed with deionized water 5 times and recovered. The prepared PVP-coated cerium dioxide nanoparticles / porous silica microbeads were dispersed in deionized water and stored in a refrigerator. Thermogravimetric analysis (TGA) confirmed that the coating weight ratio of PVP in the synthesized PVP-coated cerium dioxide nanoparticles / porous silica microbeads was approximately 8% ( Figure 10 ).
[0132] [Example 5]
[0133] Results of confirmation of ROS removal ability of ceria nanoparticles / porous silica microbeads and PVP-coated ceria nanoparticles / porous silica microbeads
[0134] The analysis of hydrogen peroxide (H2O2) and hydroxyl radical (Hydroxyl radical) was performed using porous silica microbeads without ceria nanoparticles, ceria nanoparticles / porous silica microbeads, and PVP-coated ceria nanoparticles / porous silica microbeads. The results showed that the porous silica microbeads without ceria nanoparticles had almost no ability to remove H2O2, while the two microbeads loaded with ceria nanoparticles had sufficient ROS removal ability ( Figure 11 and 12 ). This means that even after PVP coating, the ROS removal ability remains unchanged without weakening.
[0135] In order to confirm the amount of ceria nanoparticles required for porous microbeads with sufficient ROS removal properties, PVP-coated ceria nanoparticles / porous silica microbeads with 2, 4, 10, 20, 40, 100, and 200 mg of ceria nanoparticles per 1 g of microbeads were used and reacted in 2 mL of 500 μM H2O2 for 1 hour. The results confirmed that as the amount of ceria nanoparticles increased, its active oxygen (hydrogen peroxide) removal ability was enhanced ( Figure 13 ). PVP-coated ceria nanoparticles / porous silica microbeads loaded with 2 mg / g of ceria nanoparticles were almost unable to remove H2O2, while when loaded with 4 mg / g of ceria nanoparticles, the removal efficiency was about 30%, when loaded with 10 mg / g of ceria nanoparticles, the removal efficiency was about 50%, and when loaded with 20 mg / g of ceria nanoparticles, the removal efficiency was about 80% or more. When the ceria nanoparticle loading was 100 mg or more, it showed an active oxygen removal capacity of more than 90%, and there was no significant difference in the removal capacity. Therefore, in subsequent experiments, PVP-coated ceria nanoparticles / porous silica microbeads with a loading of 100 mg of ceria nanoparticles per 1 g of microbeads were prepared and used to make boxes.
[0136] [Example 6]
[0137] Results of confirmation of ROS removal ability of cerium dioxide nanoparticles / porous silica microbeads in hemoperfusion box
[0138] By creating an actual usage environment, we confirmed whether the ceria nanoparticles / porous silica microbeads can effectively operate in the box and remove ROS.
[0139] Figure 14 The following figure shows the components of the box produced by a 3D printer and the picture of the assembled box. The box for removing active oxygen in blood was made by placing 200 mg of porous microbeads inside the produced box. As an example, a box containing porous silica microbeads, cerium dioxide nanoparticles / porous silica microbeads, and PVP-coated cerium dioxide nanoparticles / porous silica microbeads was produced ( Figure 15 To test the ROS removal capacity of each cartridge, 10 mL of 2 mM H2O2 solution was repeatedly perfused and recovered, and the ROS removal efficiency was measured for 7 cycles ( Figure 16The results showed that porous silica microbeads were unable to remove H₂O₂, while ceria nanoparticles / porous silica microbeads achieved a removal efficiency of approximately 40% after one cycle, approximately 50% after two cycles, and approximately 80% and 95% after four and seven cycles, respectively. Furthermore, despite being coated with PVP polymer, the PVP-coated ceria nanoparticles / porous silica microbeads exhibited similar ROS removal efficiency as the ceria nanoparticles / porous silica microbeads. In other words, their excellent catalase-mimicking activity was confirmed even after PVP coating.
[0140] Unlike the above experiment in which the hydrogen peroxide solution flowing through the cartridge was recovered and passed through the cartridge again, a new hydrogen peroxide solution was used to flow through the cartridge each time. The ROS removal rate was measured after 7 cycles. The results showed that even with a high concentration of hydrogen peroxide solution, a removal rate of more than 60% was achieved in 7 cycles ( Figure 17 After repeating the experiment seven times, the researchers waited 24 hours and then passed the hydrogen peroxide solution through the cartridge again for the eighth, ninth, tenth, and eleventh cycles. The results confirmed that catalase mimicking activity was restored even after passing the hydrogen peroxide solution through the cartridge for eight to eleven cycles after 24 hours.
[0141] This suggests that ceria nanoparticles / porous silica microbeads and PVP-coated ceria nanoparticles / porous silica microbeads have the potential to remove ROS in future external blood cartridge systems.
[0142] [Example 7]
[0143] Comparison of ROS removal ability between porous microbeads and non-porous glass microbeads in hemoperfusion cassettes
[0144] The catalase mimicking properties of the cartridges made by loading ceria nanoparticles on non-porous glass microbeads and porous PES (polyethersulfone) polymer microbeads were compared with the catalase mimicking properties of the PVP-coated ceria nanoparticles / porous silica microbead cartridges ( Figure 18 ). Unlike the microbeads that were not loaded with ceria nanoparticles, which were unable to remove hydrogen peroxide, the box made with all the microbeads loaded with ceria nanoparticles showed the characteristics of removing hydrogen peroxide. Then, for the non-porous glass microbeads, although a certain degree of hydrogen peroxide could be removed, its efficiency was lower than that of other porous microbeads (about 40%), and when the component of the porous microbeads was changed to PES polymer, the catalase mimetic properties were still maintained at about 90%, which was confirmed to be similar to the 95% level of the box based on porous silica microbeads. This means that the porous microbeads can load a large amount of ceria nanoparticles and therefore have a better active oxygen removal ability than non-porous microbeads with the same capacity.
[0145] [Example 8]
[0146] Blood adsorption analysis results
[0147] Red blood cells in the blood can easily react with foreign substances and hemolyze or aggregate. Microbeads used for blood perfusion must not react with or destroy red blood cells before they can be used in the bloodstream. 10 mg of porous silica microbeads, cerium dioxide nanoparticles / porous silica microbeads, and PVP-coated cerium dioxide nanoparticles / porous silica microbeads were mixed with 1 mL of red blood cell solution. After reacting for 2 hours, the microbeads were separated by centrifugation, and the absorbance of the supernatant was measured. The hemolyzed red blood cells were analyzed. The results showed that all tested microbeads did not exhibit hemolytic properties ( Figure 19 and Figure 20 ).
[0148] To determine the adsorption of microbeads to red blood cells in the blood, 100 mg of porous silica microbeads, ceria nanoparticles / porous silica microbeads, and alginate, PEG, or PVP-coated ceria nanoparticles / porous silica microbeads were incubated with 10 mL of blood at 37°C for 2 hours, centrifuged, and washed three times with PBS. The microbeads were then observed. Figure 21 ) showed that porous silica microbeads and ceria nanoparticles / porous silica microbeads appeared red due to red blood cell adsorption, while alginate- and PEG-coated ceria nanoparticles / porous silica microbeads exhibited relatively low levels of red blood cell adsorption. However, PVP-coated ceria nanoparticles / porous silica microbeads exhibited virtually no red blood cell adsorption and maintained their original color, indicating no blood adsorption. In other words, PVP is considered the most suitable polymer coating for preventing microbead-blood adsorption.
[0149] [Example 9]
[0150] Evaluation of the therapeutic efficacy of PVP-coated cerium dioxide nanoparticles / porous silica microbeads in hemoperfusion boxes
[0151] In vitro blood purification was performed on rats (Rat) with sepsis induced by intravenous infusion of LPS. Figure 22 ) showed that the concentration of hydrogen peroxide released by leukocytes in the group receiving extracorporeal hemoperfusion treatment was statistically significantly lower than that in the control group ( Figure 23 ), and the blood lactate level, which indicates the severity of septic shock, also decreased significantly ( Figure 24 The mortality rate of the control group was 100% (n=7, total 7), but the survival rate of the group receiving extracorporeal hemoperfusion treatment was significantly different, with a mortality rate of 0% (n=0, total 7) ( Figure 25The mean arterial pressure (MAP) value of the group receiving extracorporeal hemoperfusion treatment was significantly higher than that of the control group ( Figure 26 ), and the amount of pressor drugs used is also less ( Figure 27 ).
Claims
1. A porous microbead for in vitro blood perfusion, characterized in that: Contains cerium dioxide nanoparticles.
2. The porous microbeads according to claim 1, wherein The porous microbeads remove active oxygen through the catalytic effect of the cerium dioxide nanoparticles.
3. The porous microbeads according to claim 1, characterized in that The size of the porous microbeads, ie, the diameter, is 1 to 1500 μm.
4. The porous microbeads according to claim 1, characterized in that The pore volume of the porous microbeads is 0.1 cm 3 / g to 13.6cm 3 / g.
5. The porous microbeads according to claim 1, characterized in that The surface area of the porous microbeads is 100 m 2 / g to 1000m 2 / g.
6. The porous microbeads according to claim 1, characterized in that The porous microbeads contain 3 mg / g or more of cerium oxide nanoparticles.
7. The porous microbeads according to claim 1, characterized in that The porous microbeads are at least one selected from the group consisting of alginate-coated porous microbeads, polyethylene glycol-coated porous microbeads, polyvinyl pyrrolidone-coated porous microbeads, and combinations thereof.
8. The porous microbeads according to claim 7, characterized in that The porous microbeads are porous microbeads coated with polyvinyl pyrrolidone.
9. An extracorporeal blood perfusion box, characterized in that: The porous microbeads according to any one of claims 1 to 8 are included.
10. The extracorporeal blood perfusion box according to claim 9, characterized in that: The volume ratio of the porous microbeads to the entire extracorporeal blood perfusion box is 50% to 90%.
11. An extracorporeal blood purification device, characterized in that: Comprising the extracorporeal blood perfusion box according to claim 9.
12. An extracorporeal blood purification method, characterized in that: include: Step (a), contacting blood separated from a subject with the porous microbeads according to any one of claims 1 to 8; Step (b), removing active oxygen from the blood using the porous microbeads; as well as Step (c), recovering the blood from which the active oxygen has been removed.
13. A method for preparing porous microbeads according to any one of claims 1 to 8, wherein the porous microbeads are used for in vitro blood perfusion, characterized in that: include: Step (a), synthesizing porous microbeads and modifying their surfaces; as well as Step (b) attaching cerium dioxide nanoparticles to the surface of the modified porous microbeads.
14. The method according to claim 13, characterized in that In the step (a), the surface of the porous microbeads is modified using a reagent comprising one or more functional groups selected from the group consisting of amine, thiol, and carboxyl groups.
15. The method according to claim 13, characterized in that The method further comprises step (c), coating the surface of the porous microbeads to which the cerium dioxide nanoparticles are attached with a polymer.
